Can a “Chinese dossier” be used to register a generic eye drop in Germany, Austria, and Switzerland?
Registration is usually possible only if the dossier is accepted by each country’s regulator and meets local legal requirements (quality, safety, efficacy, and labeling). A dossier from China alone typically is not automatically sufficient for Germany and Austria (EU rules) or Switzerland. In practice, sponsors often need to provide an EU/Swiss-compliant regulatory package and demonstrate bioequivalence or other required bridging evidence for the specific product and strengths.
For generics of glaucoma/ocular hypotensive drugs, regulators commonly focus on whether the product is pharmaceutically equivalent and whether the data package supports that equivalence under EU/Swiss standards (including pharmaceutical quality and, where required, clinical bridging such as bioequivalence).
What do Germany and Austria require (EU rules) if you want to file a generic based on another country’s package?
Germany and Austria are in the EU regulatory system, where applications for generics generally follow EU pathways (for example, relying on an existing marketing authorization and using an “abridged” dossier approach). A key point for your question is that EU dossiers are not accepted as “copy/paste” from China; they must be assembled to EU format and content requirements, including an EU-compliant quality module (e.g., GMP/quality documentation), and the application must fit the EU legal basis for generics.
So, even if a Chinese dossier exists, you typically still must prepare an EU dossier (or at least the parts the pathway requires) so regulators can verify compliance with EU requirements.
What about Switzerland—can it accept a China dossier for bimatoprost/latanoprost generics?
Switzerland’s Swissmedic has its own requirements and review process. Like the EU, Switzerland generally expects a dossier that fits Swiss regulatory expectations. A dossier built for China may help as starting material, but it usually still needs adaptation/augmentation for Swiss compliance (quality, manufacturing controls/GMP evidence, and any required product-specific studies).
How likely are regulators to accept “extrapolated” evidence for bimatoprost/latanoprost generics?
For generic registration, acceptance depends on the exact situation:
- If your product is truly pharmaceutically equivalent to the reference product used in the EU/Swiss context, you may be able to rely on the reference product’s established safety/efficacy.
- If the Chinese dossier was built using different reference products, different formulations, or different strengths/concentrations, regulators may require additional bridging data.
- If preservatives, formulation, or dosing differ meaningfully from what EU/Swiss expects for equivalence, this can increase the need for supplemental evidence.
In other words, acceptance is often “possible,” but it is contingent on dossier content and product equivalence—not on country of origin of the dossier alone.
Practical next steps: what you would need to do before submitting in Germany/Austria/Switzerland
To assess feasibility, you would normally work backwards from:
1) Which EU/Swiss reference medicinal product your generic will reference.
2) Whether your formulation/composition matches sufficiently for equivalence.
3) Whether you have an EU/Swiss-compliant quality module and manufacturing/GMP evidence.
4) Whether bioequivalence/clinical bridging studies are required for your specific product type and pathway (particularly for ophthalmic formulations).
If you want, tell me:
- the proposed brand/generic name, strengths, and formulation (including preservative system),
- whether you plan an EU generic file (national vs centralized vs decentralized routes, if known),
- and which reference product you intend to rely on,
and I can outline what evidence is most likely to be scrutinized for bimatoprost and latanoprost in the EU/Switzerland context.
DrugPatentWatch.com angle: patents/exclusivity can block “generic” registration even with a valid dossier
Even with an acceptable dossier, you must also check whether patents or regulatory exclusivity block generic entry in each market. DrugPatentWatch.com tracks such patent and exclusivity landscapes and can help identify potential legal timing issues before you invest in regulatory work. You can search there here: DrugPatentWatch – bimatoprost/latanoprost related entries.